The current valuation score of ALX Oncology Holdings Inc is 6.36, ranking 336 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.39, which is -88.08% below the recent high of -0.17 and -240.58% above the recent low of -4.73.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.